Jim Cramer on Vertex Pharmaceuticals Incorporated (VRTX)’s Suzetrigine: ‘I Don’t See A Lot Of Upside Because That Was The Drug Of The Future For Vertex’
We recently compiled a list of the Jim Cramer Shed Light on These 9 Stocks. In this article, we are going to take a look at ...
BMO raises Vertex stock price target to $545 from $520
BMO Capital Markets increased its price target on Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) shares, moving the ...
Vertex Pharmaceuticals Shares Are Up Today: What's Going On?
Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) shares are trading higher Friday following two major developments that strengthen ...
Vertex Pharmaceuticals' non-opioid pain medication gets FDA approval
A non-opioid pain medication made by Vertex Pharmaceuticals has received approval for adults from the Food and Drug ...
American Association of Individual Investors2d
Which Is a Better Investment, Natera, Inc. or Vertex Pharmaceuticals Incorporated Stock?
Learn more about whether Natera, Inc. or Vertex Pharmaceuticals Incorporated is a better investment based on AAII's A+ ...
Vertex Pharmaceuticals stock is soaring. The FDA just approved its potentially game-changing pain treatment.
Shares of Vertex Pharmaceuticals Inc. surged ahead of Friday’s market open after the Food and Drug Administration approved the company’s non-opioid pain treatment.
Vertex Pharmaceuticals Incorporated Investigation Ongoing: Contact Levi & Korsinsky About Potential Securities Fraud Allegations - VRTX
NEW YORK, NY / ACCESS Newswire / January 31, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Vertex ...
AFP1d
Vertex Announces FDA Approval of JOURNAVX™ (suzetrigine), a First-in-Class Treatment for Adults With Moderate-to-Severe Acute Pain
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has ...
Buy Rating for Vertex Pharmaceuticals: FDA Approval of Journavx Boosts Market Potential and Stock Price Target
Analyst Andrew Fein of H.C. Wainwright maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report), boosting the price target to ...
Pharmaceutical Technology on MSN21h
FDA approves Vertex’s acute pain treatment Journavx
The FDA has approved Vertex Pharmaceuticals’ oral Journavx (suzetrigine) to treat adults with moderate-to-severe acute pain.
BioWorld7h
Vertex wins FDA nod for Journavx, new mechanism for acute pain
An effort two decades in the making, Vertex Pharmaceuticals Inc.’s suzetrigine gained U.S. FDA approval as the first drug targeting the NaV1.8 pain signal. Branded Journavx, the oral small molecule is ...
Investing1d
Vertex Pharma shares jump on FDA approval for its non-opioid painkiller
Investing.com-- Vertex Pharmaceuticals Inc (NASDAQ: VRTX) shares jumped in extended trading on Thursday, following the U.S.